New treatments for celiac disease are closer than ever — but FDA approval is only half the battle. Without clear policies on who qualifies, how diagnosis is confirmed, and whether insurance will actually pay, promising therapies could sit just out of reach for the patients who need them most.
That gap between “approved drug” and “patient who can access it” was the focus of the Celiac Disease Foundation’s 2026 National Celiac Disease Policy Symposium, held virtually on June 12, 2026. Co-hosted with the Society for the Study of Celiac Disease, the event brought together a group that rarely shares the same room: gastroenterologists, diagnostic specialists, FDA representatives, and health insurance executives — known in policy circles as payers.
The theme was direct: “From Diagnosis to Coverage: Aligning Policy for Celiac Disease Therapeutics.” The message was equally plain. The science is advancing. The policy infrastructure needed to actually deliver those gains to patients is not.
What This Means for You
As the parent of a child with celiac disease, I have spent years watching my son manage a condition with exactly one FDA-approved treatment: a strict, lifelong gluten-free diet. The good news is that real pharmaceutical options — drugs that could protect celiac patients from accidental gluten exposure or reduce intestinal damage — are moving through clinical trials. The harder truth is that a drug reaching FDA approval does not automatically mean it reaches your child’s pharmacy.
Here is the core problem the symposium addressed. When a new drug is approved, insurers need criteria to decide who qualifies for coverage. Those criteria depend on how patients are diagnosed — and celiac diagnosis is messier than most people realize. Some patients are diagnosed by intestinal biopsy. Some through blood tests alone. Some through genetic testing combined with symptoms. If there is no agreed-upon standard for what a confirmed celiac diagnosis looks like, insurers have no consistent basis for coverage decisions. That ambiguity gives payers a reason to delay or deny coverage while they wait for clarity that may never come on its own.
Doctors also need to know the drug exists, which patients are candidates, and how to prescribe it appropriately. That requires education at scale — across primary care physicians, gastroenterologists, and pediatric specialists. All of this infrastructure has to be built before the first prescription is written, or the lag between approval and real-world access will stretch for years.
The symposium was framed as a first step: getting key stakeholders aligned early, before drugs are approved, so the framework for fair and timely coverage is already in place when the moment arrives. Building on the advocacy momentum covered in Celiac Disease Advocates Take to Capitol Hill for our 2026 Advocacy Summit, this event signals that the celiac community is moving beyond lobbying for attention. It is now working to shape the specific systems that will determine whether new therapies actually reach patients.
Key Takeaways
- New celiac treatments are advancing through clinical trials, but FDA approval alone does not guarantee patient access.
- Insurance coverage requires clear, agreed-upon diagnostic criteria — and celiac disease currently lacks a single consistent standard.
- The 2026 Policy Symposium brought together doctors, regulators, and insurers to build that framework now, before drugs are approved.
- Getting a treatment to patients requires coordinating science, policy, and insurance systems at the same time — not one after another.
- The celiac community is shifting from reacting to the system to shaping it proactively.
The Science
Want to understand how this actually works under the hood? We’ll walk you through the policy and diagnostic details below and define every term. No medical degree required.
Why Diagnostic Standards Drive Everything Downstream
Celiac disease can be confirmed through several methods, and the lack of a single universal pathway creates serious complications for coverage decisions.
The traditional approach is an intestinal biopsy — a procedure where a gastroenterologist uses an endoscope to collect tissue samples from the small intestine and examine them for damage to the villi (tiny finger-like projections that absorb nutrients). Flattened or destroyed villi are a hallmark of untreated celiac disease.
Biopsies are invasive and expensive. Many patients — particularly children — are now diagnosed through a combination of serology tests (blood tests that detect antibodies like tissue transglutaminase IgA, or tTG-IgA) and genetic markers (HLA-DQ2 and HLA-DQ8 — the gene variants associated with celiac susceptibility). European clinical guidelines already allow non-biopsy diagnosis under certain conditions. U.S. practice varies by provider.
When a payer evaluates whether a patient qualifies for a new drug, they typically require documented diagnosis. If “documented” means biopsy to one insurer and blood test plus symptoms to another, coverage becomes arbitrary. Patients with equivalent disease severity may be approved or denied based entirely on how their chart was written — not on how sick they are. This is the inconsistency the symposium aimed to resolve: building consensus around a clear, evidence-based definition of confirmed celiac disease that payers can apply consistently across the country.
The Coverage Determination Process
Even with diagnostic standards in place, a drug still has to move through a formal coverage determination — the process by which an insurer decides whether a therapy is covered, under what conditions, and at what cost to the patient.
For celiac disease, several factors complicate this step. Celiac affects roughly 1% of the population, with many cases still undiagnosed. Smaller patient populations often mean less insurer familiarity with the disease and its management, which can slow coverage decisions or produce inconsistent rulings across plans.
There is also the comparison problem. The existing treatment — the gluten-free diet — costs insurers nothing directly. Any pharmaceutical therapy will have a price, and payers will require evidence not just that the drug works, but that it delivers meaningful benefit beyond dietary management alone. That means clinical trials need to capture the specific kinds of outcome data insurers find persuasive — not just data that satisfies an FDA reviewer. When drug developers know this in advance, they can design trials to produce it. When they find out after approval, the coverage fight can take years.
Physician Education as Infrastructure
A third challenge the symposium tackled: even when a drug is approved and covered, it needs to be prescribed. Celiac disease is managed by a wide range of providers — gastroenterologists, registered dietitians, and increasingly primary care physicians who may see a patient’s celiac only in passing. Each of these providers needs to understand which patients are candidates for a new therapy, how to monitor outcomes, and how treatment interacts with ongoing dietary management.
That education does not build itself. It requires deliberate infrastructure: clinical guidelines, professional society recommendations, and continuing medical education programs. The Society for the Study of Celiac Disease was at the table specifically because that organization shapes how gastroenterologists learn and practice. Getting physician education in place before approval — rather than scrambling to build it afterward — can meaningfully shorten the path from regulatory clearance to actual prescription.
This symposium did not make headlines the way a drug approval would. But what happened in that virtual room on June 12 may matter as much to celiac families as any clinical trial result. Science discovers treatments. Policy determines who receives them.
The Massachusetts State House Briefing on celiac policy reform showed how local advocates are pushing for structural change from the state level up. The policy symposium shows the same effort at the federal and industry level. Both are necessary. The celiac community is learning — rightly — that the pipeline does not end in the lab.
I want my son to have access to every effective treatment that becomes available as he grows up. That will not happen by accident. It will happen because the celiac community did this kind of difficult, unglamorous policy work years before the prescriptions were ready to be written.
Related Coverage
- Celiac Disease Advocates Take to Capitol Hill for our 2026 Advocacy Summit
- Massachusetts State House Briefing Highlights Urgent Need for Celiac Disease Policy Reform
- How the Celiac Disease Foundation and Biopharma Partners Are Turning Patient Voice Into Scientific Evidence
References
- Celiac Disease Foundation. “Getting Drugs for Celiac Disease to Patients…It will Take More than Science: Key Takeaways from the 2026 National Celiac Disease Policy Symposium.” June 18, 2026. celiac.org